3,23-Dioxo-9,19-cyclolanost-24-en-26-oic acidCAS# 870456-88-5 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 870456-88-5 | SDF | Download SDF |
PubChem ID | 21593999 | Appearance | Powder |
Formula | C30H44O4 | M.Wt | 468.7 |
Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
SMILES | CC(CC(=O)C=C(C)C(=O)O)C1CCC2(C1(CCC34C2CCC5C3(C4)CCC(=O)C5(C)C)C)C | ||
Standard InChIKey | PJYWFBGSJPGTAM-ACKRQZOBSA-N | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. 3,23-Dioxo-9,19-cyclolanost-24-en-26-oic acid inhibits the MRCKα kinase with Kd50 of 3.0 uM, it also inhibits the MRCKβ kinase with Kd50 of 3.2 uM; the role of Kinases in cancer onset and progression has made kinases a target for the control of some cancers, suggests that it may possess anticancer activity. |
3,23-Dioxo-9,19-cyclolanost-24-en-26-oic acid Dilution Calculator
3,23-Dioxo-9,19-cyclolanost-24-en-26-oic acid Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.1336 mL | 10.6678 mL | 21.3356 mL | 42.6712 mL | 53.339 mL |
5 mM | 0.4267 mL | 2.1336 mL | 4.2671 mL | 8.5342 mL | 10.6678 mL |
10 mM | 0.2134 mL | 1.0668 mL | 2.1336 mL | 4.2671 mL | 5.3339 mL |
50 mM | 0.0427 mL | 0.2134 mL | 0.4267 mL | 0.8534 mL | 1.0668 mL |
100 mM | 0.0213 mL | 0.1067 mL | 0.2134 mL | 0.4267 mL | 0.5334 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- CAL-101 (Idelalisib, GS-1101)
Catalog No.:BCC1270
CAS No.:870281-82-6
- Acalisib (GS-9820)
Catalog No.:BCC6384
CAS No.:870281-34-8
- Apilimod mesylate
Catalog No.:BCC5287
CAS No.:870087-36-8
- Tozadenant
Catalog No.:BCC2011
CAS No.:870070-55-6
- A 839977
Catalog No.:BCC4290
CAS No.:870061-27-1
- xylitol pentacetate
Catalog No.:BCN6267
CAS No.:13437-68-8
- Inositol
Catalog No.:BCN8471
CAS No.:87-89-8
- D-Mannitol busulfan
Catalog No.:BCN3789
CAS No.:1187-00-4
- Tartaric acid
Catalog No.:BCN3824
CAS No.:87-69-4
- Pyrogallol
Catalog No.:BCN4424
CAS No.:87-66-1
- Gramine
Catalog No.:BCN4959
CAS No.:87-52-5
- trans-Caryophyllene
Catalog No.:BCN2644
CAS No.:87-44-5
- Bis-5,5-nortrachelogenin
Catalog No.:BCN6516
CAS No.:870480-56-1
- GW2580
Catalog No.:BCC1096
CAS No.:870483-87-7
- Ritanserin
Catalog No.:BCC7214
CAS No.:87051-43-2
- Zeylasteral
Catalog No.:BCN3065
CAS No.:87064-16-2
- Euphohelioscopin A
Catalog No.:BCN6501
CAS No.:87064-61-7
- PAP-1
Catalog No.:BCC1836
CAS No.:870653-45-5
- AC 261066
Catalog No.:BCC7848
CAS No.:870773-76-5
- Leptomycin B
Catalog No.:BCC7223
CAS No.:87081-35-4
- MK 0893
Catalog No.:BCC1752
CAS No.:870823-12-4
- E 2012
Catalog No.:BCC1540
CAS No.:870843-42-8
- Mulberrofuran G
Catalog No.:BCN3693
CAS No.:87085-00-5
- 5-Hydroxy-1,7-diphenyl-6-hepten-3-one
Catalog No.:BCN1321
CAS No.:87095-74-7
Cycloartane anticancer activity
Cancer Res., 2014, 74(19 ):1754-1754.
Cycloart-23-ene-3,25-diol (1), Cycloartane-3,24,25-triol (2), Cycloart-25-ene-3,24-diol (3), 3,23-Dioxo-9,19-cyclolanost-24-en-26-oic acid (4), 24,25-Dihydroxycycloartan-3-one (5) inhibited the MRCKα kinase with Kd of 0.21 μM, 0.25μM, 0.36 μM, 3.0 μM, and 2.1 μM respectively. Hydroxycycloart-23-en-3-one,25, (6) showed no inhibition against the MRCKα kinase. Compounds 1, 3, 4, 5 inhibited the MRCKβ kinase with Kd of 4.7 μM, 1.10 μM, 3.2 μM, and 9.8 μM, respectively. Three of the six cycloartanes exhibited antiproliferation activity against two prostate and breast cancer cell lines each.In conclusion, cycloart-23-ene-3,25-diol (1) showed the most promising activity against the MRCKα/β kinase out of the 6 cycloartanes screened demonstrating an interesting structure activity relationship profile when compared with the other molecules. Cycloart-23-ene-3,25-diol (1) deserves further studies to determine its in vivo efficacy and safety.